Grade 3 tumor’s (100% in patients with pCR vs. 0 % in non-responders, p=0.0004), PR-negative BC (100% vs. 43%, p=0.010), and tumors with mutated TP53 (67% vs. 24%, p=0.042) better responded to chemotherapy. This evidence concerns the gene TP53 and breast cancer.